The purpose of this study is to quantify the dose of aerosol medication deposited in the
lungs of lung transplant recipients receiving a single nebulized treatment of aerosolized
Abelcet® (lipid complexed amphotericin-B). This study is being performed to determine the
range of deposited doses and patterns of distribution that could be expected in this
population so that the ultimate efficacy of this preparation can be evaluated. A radioisotope
technique will be utilized to track the medication dose. The study will include 12 subjects
who will perform one testing session lasting approximately 3 hours. An Investigational New
Drug Application (IND) detailing this protocol has been submitted by the principal
investigator (PI) and approved by the Food and Drug Administration [FDA] (72,521).